B细胞-话题@MedSci

#B细胞#

314篇内容 | 4718人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1273340, encodeId=40cb12e334013, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=J Gastroenterology：PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响, objectType=article, longId=187601, objectId=3fc418e60132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fc418e60132, replyNumber=0, likeNumber=105, createdTime=2020-02-08, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fc418e60132, moduleTitle=J Gastroenterology：PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fc418e60132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273339, encodeId=9c5112e33399e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, objectType=article, longId=187159, objectId=649918e159e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=649918e159e2, replyNumber=0, likeNumber=67, createdTime=2020-02-03, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=649918e159e2, moduleTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=649918e159e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273338, encodeId=e5a212e333895, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Incyte以11亿美元收购MorphoSys的抗CD19单抗tafasitamab，用于治疗B细胞淋巴瘤, objectType=article, longId=186397, objectId=d68418639efd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d68418639efd, replyNumber=0, likeNumber=71, createdTime=2020-01-18, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d68418639efd, moduleTitle=Incyte以11亿美元收购MorphoSys的抗CD19单抗tafasitamab，用于治疗B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d68418639efd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273337, encodeId=753e12e333740, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=邱录贵教授：利妥昔单抗是淋巴瘤免疫化疗的“基石”药物，为惰性B细胞淋巴瘤带来显著生存获益丨2020年白血病·淋巴瘤高峰论坛, objectType=article, longId=186322, objectId=1d521863220b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d521863220b, replyNumber=0, likeNumber=84, createdTime=2020-01-17, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d521863220b, moduleTitle=邱录贵教授：利妥昔单抗是淋巴瘤免疫化疗的“基石”药物，为惰性B细胞淋巴瘤带来显著生存获益丨2020年白血病·淋巴瘤高峰论坛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d521863220b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273336, encodeId=fdbd12e3336fd, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nature：为什么女性免疫力更强？也许与B细胞“抗体工厂”有关, objectType=article, longId=186313, objectId=7b171863132c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b171863132c, replyNumber=0, likeNumber=68, createdTime=2020-01-17, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b171863132c, moduleTitle=Nature：为什么女性免疫力更强？也许与B细胞“抗体工厂”有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b171863132c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273335, encodeId=3f9212e333586, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=林桐榆教授：复发难治弥漫大B细胞淋巴瘤治疗关键与挑战, objectType=article, longId=186206, objectId=9fb1186206ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fb1186206ed, replyNumber=0, likeNumber=67, createdTime=2020-01-15, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fb1186206ed, moduleTitle=林桐榆教授：复发难治弥漫大B细胞淋巴瘤治疗关键与挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fb1186206ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273334, encodeId=dba812e333461, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, objectType=article, longId=186029, objectId=4575186029eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4575186029eb, replyNumber=0, likeNumber=75, createdTime=2020-01-11, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4575186029eb, moduleTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4575186029eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273333, encodeId=cece12e33338a, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NCCN临床实践指南：儿童侵袭性成熟B细胞淋巴瘤（2020.V1）, objectType=article, longId=185482, objectId=aa7a18548291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa7a18548291, replyNumber=0, likeNumber=23, createdTime=2020-01-01, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa7a18548291, moduleTitle=NCCN临床实践指南：儿童侵袭性成熟B细胞淋巴瘤（2020.V1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa7a18548291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273332, encodeId=e3d812e33325d, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Diabetologia：在NOD小鼠抗cd20治疗后，表型明显的抗胰岛素B细胞在胰岛重新增殖？, objectType=article, longId=185165, objectId=014518516583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=014518516583, replyNumber=0, likeNumber=124, createdTime=2019-12-26, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=014518516583, moduleTitle=Diabetologia：在NOD小鼠抗cd20治疗后，表型明显的抗胰岛素B细胞在胰岛重新增殖？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=014518516583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273331, encodeId=a95a12e3331a3, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Lancet：R-CHOP化疗联合利妥昔单抗治疗侵袭性B细胞非霍奇金淋巴瘤, objectType=article, longId=185002, objectId=956e185002ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=956e185002ad, replyNumber=0, likeNumber=74, createdTime=2019-12-22, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=956e185002ad, moduleTitle=Lancet：R-CHOP化疗联合利妥昔单抗治疗侵袭性B细胞非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=956e185002ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273330, encodeId=1f0c12e33307d, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Arthritis Rheumatol：类风湿性关节炎的B细胞滑膜炎和临床表型, objectType=article, longId=184217, objectId=58b418421ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58b418421ed6, replyNumber=0, likeNumber=63, createdTime=2019-12-07, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58b418421ed6, moduleTitle=Arthritis Rheumatol：类风湿性关节炎的B细胞滑膜炎和临床表型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58b418421ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273329, encodeId=31d312e3329d4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定, objectType=article, longId=183346, objectId=525e183346c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525e183346c6, replyNumber=0, likeNumber=126, createdTime=2019-11-23, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525e183346c6, moduleTitle=日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525e183346c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273328, encodeId=668e12e33284e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：序贯输注CAR19/22 T细胞治疗B细胞恶性肿瘤，有效减少抗原逃逸复发, objectType=article, longId=182246, objectId=c8d018224602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8d018224602, replyNumber=0, likeNumber=71, createdTime=2019-11-03, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8d018224602, moduleTitle=Blood：序贯输注CAR19/22 T细胞治疗B细胞恶性肿瘤，有效减少抗原逃逸复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8d018224602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273327, encodeId=854a12e3327db, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：原发性纵隔大B细胞淋巴瘤全基因组分析揭示新的致病变异, objectType=article, longId=182129, objectId=70891821292f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70891821292f, replyNumber=0, likeNumber=58, createdTime=2019-10-31, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70891821292f, moduleTitle=Blood：原发性纵隔大B细胞淋巴瘤全基因组分析揭示新的致病变异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70891821292f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273326, encodeId=da7112e332653, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=【2019 CSCO】国内白血病·淋巴瘤专场：聚焦淋巴瘤治疗前沿，BTK抑制剂在B细胞淋巴瘤中应用前景广阔, objectType=article, longId=180451, objectId=021e180451ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=021e180451ba, replyNumber=0, likeNumber=66, createdTime=2019-10-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=021e180451ba, moduleTitle=【2019 CSCO】国内白血病·淋巴瘤专场：聚焦淋巴瘤治疗前沿，BTK抑制剂在B细胞淋巴瘤中应用前景广阔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=021e180451ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273325, encodeId=f19812e332573, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：Ublituximab联合Umbralisib治疗复发性/难治性B细胞NHL和CLL的安全性评估, objectType=article, longId=180400, objectId=2b0b180400c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b0b180400c6, replyNumber=0, likeNumber=109, createdTime=2019-10-04, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b0b180400c6, moduleTitle=Blood：Ublituximab联合Umbralisib治疗复发性/难治性B细胞NHL和CLL的安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b0b180400c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273324, encodeId=20bf12e332475, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Sci tranal med：BAFF-R靶向CAR T细胞疗法可克服B细胞恶性肿瘤的CD19抗原缺失, objectType=article, longId=180381, objectId=e0141803814a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0141803814a, replyNumber=0, likeNumber=63, createdTime=2019-10-03, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0141803814a, moduleTitle=Sci tranal med：BAFF-R靶向CAR T细胞疗法可克服B细胞恶性肿瘤的CD19抗原缺失, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0141803814a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273323, encodeId=90e212e332399, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：B细胞IRF4表达不足通过增强肿瘤免疫逃逸加速CLL的进展, objectType=article, longId=179944, objectId=d6a11e9944a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6a11e9944a1, replyNumber=0, likeNumber=90, createdTime=2019-09-25, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6a11e9944a1, moduleTitle=Blood：B细胞IRF4表达不足通过增强肿瘤免疫逃逸加速CLL的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6a11e9944a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273322, encodeId=41e912e3322a6, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=伊布替尼治疗B细胞恶性肿瘤中国专家共识（2019年版）, objectType=article, longId=179896, objectId=248a1e9896b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=248a1e9896b0, replyNumber=0, likeNumber=25, createdTime=2019-09-24, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=248a1e9896b0, moduleTitle=伊布替尼治疗B细胞恶性肿瘤中国专家共识（2019年版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=248a1e9896b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273321, encodeId=bc4212e3321c6, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nat Commun：B细胞带来危机与转机，黑素瘤免疫疗法何去何从, objectType=article, longId=179861, objectId=018b1e9861c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=018b1e9861c0, replyNumber=0, likeNumber=55, createdTime=2019-09-24, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=018b1e9861c0, moduleTitle=Nat Commun：B细胞带来危机与转机，黑素瘤免疫疗法何去何从, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=018b1e9861c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B细胞

2020-05-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

J Gastroenterology：PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响

2020-02-08

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据

2020-02-03

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Incyte以11亿美元收购MorphoSys的抗CD19单抗tafasitamab，用于治疗B细胞淋巴瘤

2020-01-18

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

邱录贵教授：利妥昔单抗是淋巴瘤免疫化疗的“基石”药物，为惰性B细胞淋巴瘤带来显著生存获益丨2020年白血病·淋巴瘤高峰论坛

2020-01-17

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nature：为什么女性免疫力更强？也许与B细胞“抗体工厂”有关

2020-01-17

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

林桐榆教授：复发难治弥漫大B细胞淋巴瘤治疗关键与挑战

2020-01-15

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功

2020-01-11

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

NCCN临床实践指南：儿童侵袭性成熟B细胞淋巴瘤（2020.V1）

2020-01-01

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Diabetologia：在NOD小鼠抗cd20治疗后，表型明显的抗胰岛素B细胞在胰岛重新增殖？

2019-12-26

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Lancet：R-CHOP化疗联合利妥昔单抗治疗侵袭性B细胞非霍奇金淋巴瘤

2019-12-22

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Arthritis Rheumatol：类风湿性关节炎的B细胞滑膜炎和临床表型

2019-12-07

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定

2019-11-23

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：序贯输注CAR19/22 T细胞治疗B细胞恶性肿瘤，有效减少抗原逃逸复发

2019-11-03

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：原发性纵隔大B细胞淋巴瘤全基因组分析揭示新的致病变异

2019-10-31

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

【2019 CSCO】国内白血病·淋巴瘤专场：聚焦淋巴瘤治疗前沿，BTK抑制剂在B细胞淋巴瘤中应用前景广阔

2019-10-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：Ublituximab联合Umbralisib治疗复发性/难治性B细胞NHL和CLL的安全性评估

2019-10-04

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Sci tranal med：BAFF-R靶向CAR T细胞疗法可克服B细胞恶性肿瘤的CD19抗原缺失

2019-10-03

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：B细胞IRF4表达不足通过增强肿瘤免疫逃逸加速CLL的进展

2019-09-25

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

伊布替尼治疗B细胞恶性肿瘤中国专家共识（2019年版）

2019-09-24

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nat Commun：B细胞带来危机与转机，黑素瘤免疫疗法何去何从

2019-09-24

科室
- - 订阅+
  - 更多科室
工具
服务